Better Heath, Brighter Future

Takeda Climbs Mount Kilimanjaro with Multiple Myeloma Research Foundation and CURE to Support Moving Mountains for Multiple Myeloma

Click here to view the gallery

Patients are at the center of everything we do

At Takeda, patients motivate and inspire us to do more

Takeda is a global pharmaceutical leader founded by Chobei Takeda I in 1781 in Osaka, Japan.

We focus on innovative medicines in gastroenterology, oncology, central nervous system, cardiovascular and metabolic, as well as vaccines. Our portfolio of quality, established prescription and over-the-counter medicines helps patients around the world.

Takeda’s mature markets – Japan, United States and Europe – remain strong cornerstones of our business as we continue to grow our presence in emerging markets, such as Brazil, Russia and China.

Every day more than 30,000 Takeda employees work towards discovering, developing and delivering medicines that will improve patients’ lives.

We strive towards better health for people worldwide through leading innovation in medicine.

“I couldn’t go out with my family, I was advised to stop running. Nothing on the list of treatment options was working, I was dreading surgery but

I was running
out of options...”

John had always been an avid runner.
When ulcerative colitis struck, the pain, diarrhea, weight loss and exhaustion put an end to what he enjoyed doing most.

“ I’m able to enjoy activities with my family, I’m running again,
I’m back on track.”
John McGourty
Electrician & Lifelong Runner

The burden of ulcerative colitis and Crohn’s disease

5 million
patients affected worldwide*

326,000
new cases diagnosed in Europe and the U.S.
every year**

* European Crohn’s and Colitis Organisation (ecco-ibd.eu) ** Crohn’s & Colitis Foundation of America (ccfa.org) and Burich J. et al. Journal of Crohn’s and Colitis (2013) 7, 322–337

Striving towards better health

We innovate to improve patients' lives.

Diseases can be very debilitating and restricting to a patient. It is this understanding of the impact of disease on a person’s life that drives us to discover and develop innovative treatments.

At Takeda, we continually adapt to ensure we are best-in-class in everything we do. We are agile and respond to what patients and physicians need.

We have four defined priorities: Patients at the center, Trust with our customers and patients, Reputation of our company and heritage and Business Performance for our shareholders. These are built on and incorporate our company values, Takeda-ism: Integrity, Fairness, Honesty and Perseverance. These values are integral to our business and how we conduct everything we do.

Takeda’s near-term growth will be driven by our focus in three areas:

• Gastroenterology
• Oncology
• Value brands* in almost 40 countries within the emerging markets

*Off-patent brands and over-the-counter products

Takeda’s 25-year leadership in gastroenterology

Takeda is a leader in gastroenterology.

In the 1990s, Takeda pioneered two of the most widely used proton pump inhibitors for acid-related diseases: PREVACID® (lansoprazole) and pantoprazole. The impact of this depth of knowledge and experience in gastroenterology continues today.

ENTYVIO® (vedolizumab), launched in 2014, demonstrates our capabilities and expansion into the specialty care market in gastroenterology and biologics. TAKECAB® (vonoprazan fumarate), launched in 2015, is our first-in-class potassium competitive acid blocker in Japan.

Over the next few years we expect to conduct more than 40 ongoing clinical trials across this therapeutic area as we continue to discover and develop more treatments and products to improve the health of patients with gastrointestinal disorders.

“ I’m one of the lucky ones – I’m finding I’m re-learning how to look ahead.
I thank my lucky stars
every day!”

Carol Jarvis
Musician

Carol, a professional musician, has shared the stage with such performers as Sting, Seal and the London Symphony Orchestra. Her career was interrupted with the discovery of a lump in her neck and a diagnosis of Hodgkin lymphoma.

Over the next ten years, Carol went through multiple rounds of chemotherapy, radiotherapy and other treatments but her cancer did not respond.

Hodgkin lymphoma

66,000
new cases diagnosed worldwide in 2012*

25,500
lives lost from the disease in 2012*

* American Cancer Society (cancer.org) and WHO Globocan statistics (globocan.iarc.fr)

“ Understanding the biology of the disease and developing targeted therapies have changed the way we approach treating cancer for patients like Carol. ”

Professor John Radford
Institute of Cancer Sciences, Manchester University
The Christie NHS Foundation Trust

Delivering a brighter future

Our scientific endeavor aims to help patients live their lives to the fullest

Takeda is at the forefront of transforming cancer into a manageable disease that we aspire to cure. We have decades of experience in helping patients diagnosed with cancer, with our proven therapies that include: VELCADE® (bortezomib) for multiple myeloma and mantle cell lymphoma; ADCETRIS® (brentuximab vedotin) for relapsed and refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma; leuprorelin for prostate cancer; MEPACT® (mifamurtide) for osteosarcoma and VECTIBIX® (panitumumab) for metastatic colorectal cancer.

One of our guiding principles is “uncompromising innovation regardless of source,” which means we complement our own research and expertise with external partnerships, collaborations or acquisitions. This is illustrated through a licensing agreement we completed with ImmunoGen, Inc., in March 2015.

Through this collaboration we are able to use state-of-the-art antibody-drug conjugate technology to develop targeted anticancer therapies and to strive to bring novel agents and treatments to patients.

Products in Emerging Markets

Area Value Brands* Innovative Products
Gastroenterology Pantoprazole ENTYVIO®
DEXILANT®
(dexlansoprazole)
Oncology Leuprorelin ADCETRIS®
MEPACT®
Cardiovascular
& Metabolic
ACTOS®
(pioglitazone)
NESINA®
(alogliptin)
Over-the-counter NEOSALDINA®
(metamizole/
isometheptene/
caffeine)
CARDIOMAGNYL®
(acetylsalicylic acid and
magnesium hydroxide)
 
*Off-patent brands and over-the-counter products

10,000+
Takeda employees in emerging markets

Renewed focus on
access to medicines

300
Products sold in the emerging markets

Approx. 90%
of future growth of the pharmaceutical market
within the emerging markets will come from
the ~40 countries where Takeda has a
legal presence

Meeting growing needs

A tailored approach to emerging markets

Emerging markets are characterized by a broad diversity of patient demands and country-specific challenges. These markets are also highly dynamic with increasingly affluent populations, growing healthcare budgets and a rapidly rising demand for healthcare services and medicines. The burden on healthcare services is escalating with the prevalence of chronic conditions such as hypertension and diabetes.

Takeda is among the fastest growing multinational pharmaceutical companies in the emerging markets.

Our portfolio is tailored to address the local needs of each market with a range of products, both prescription and over-the-counter, tackling diseases in areas that include gastroenterology, metabolic and oncology.

Our value brands* are trusted and recognized for quality through the Takeda name. We provide innovative products for countries within the emerging markets and also include them in launch and marketing plans for all R&D pipeline product candidates.

This approach is supported by an emphasis on strong local leadership, making us a respected and preferred employer in these markets.

*Off-patent brands and over-the-counter products

Takeda through the years

1781
1915
1962
1990s
Since 2000

Founded in Osaka, Japan

Opened research and development laboratories

Entered overseas markets

Built leadership position in gastroenterology, oncology and cardiovascular and metabolic with a number of innovative product launches

Accelerated globalization including entering emerging markets

Takeda around the world

Emerging Markets +10.0%**

Others§ –3.1%*

Europe and Canada +5.4%*

Japan OTC

Japan -4.1%*

United States +14.5%*

 

Emerging Markets +10.0%**

Takeda is among the fastest growing multinational pharmaceutical companies in the emerging markets. Our portfolio is tailored to address the local needs of each market with a range of products both prescription and over-the-counter. These tackle diseases in gastroenterology, metabolic and oncology.

 

Japan –4.1%*

As a leading pharmaceutical company in Japan, Takeda plans to maintain our top share in the prescription drug market driven by growth from new products such as AZILVA® (azilsartan), TAKECAB®, ZAFATEK® (trelagliptin succinate) and ADCETRIS®. In addition, our OTC business continues to build our growth centered on core brands such as ALINAMIN® (vitamin products) and BENZA® (cold relief products).

 

Europe and Canada +5.4%*

In Europe and Canada, Takeda is evolving into an agile specialty care provider, driven by our innovations in gastroenterology and oncology such as ENTYVIO® and ADCETRIS®. The European Medicines Agency has granted accelerated assessment to ixazomib for the treatment of relapsed and/or refractory multiple myeloma. We continue to build our capabilities to provide improved customer service and patient care.

 

United States +14.5%*

Takeda continues on its growth path in the United States with a number of new products. In 2014 we introduced ENTYVIO® for ulcerative colitis and Crohn’s disease; BRINTELLIX® (vortioxetine) for major depressive disorder and CONTRAVE® (naltrexone HCl and bupropion HCl) for obesity. We also recently launched NINLARO® (ixazomib) to treat multiple myeloma.

Takeda around the world

Others -3.1%

Japan OTC

Emerging Markets +10.0%

Japan -4.1%

Europe and Canada

United States +14.5%

 

Emerging Markets +10.0%**

Takeda is among the fastest growing multinational pharmaceutical companies in the emerging markets. Our portfolio is tailored to address the local needs of each market with a range of products both prescription and over-the-counter. These tackle diseases in gastroenterology, metabolic and oncology.

 

Japan –4.1%*

As a leading pharmaceutical company in Japan, Takeda plans to maintain our top share in the prescription drug market driven by growth from new products such as AZILVA® (azilsartan), TAKECAB®, ZAFATEK® (trelagliptin succinate) and ADCETRIS®. In addition, our OTC business continues to build our growth centered on core brands such as ALINAMIN® (vitamin products) and BENZA® (cold relief products).

 

Europe and Canada +5.4%*

In Europe and Canada, Takeda is evolving into an agile specialty care provider, driven by our innovations in gastroenterology and oncology such as ENTYVIO® and ADCETRIS®. The European Medicines Agency has granted accelerated assessment to ixazomib for the treatment of relapsed and/or refractory multiple myeloma. We continue to build our capabilities to provide improved customer service and patient care.

 

United States +14.5%*

Takeda continues on its growth path in the United States with a number of new products. In 2014 we introduced ENTYVIO® for ulcerative colitis and Crohn’s disease; BRINTELLIX® (vortioxetine) for major depressive disorder and CONTRAVE® (naltrexone HCl and bupropion HCl) for obesity. We also recently launched NINLARO® (ixazomib) to treat multiple myeloma.

Oncology

Takeda is at the forefront of transforming cancer into a manageable disease that we aspire to cure. As a company, we have decades of experience and proven therapies on the market that include: VELCADE®, ADCETRIS®, leuprorelin, MEPACT® and VECTIBIX®.

Vaccines

Takeda’s Vaccine business unit is focused on protecting the health of people around the world by addressing some of the most infectious diseases today. We are working to develop vaccine candidates against dengue virus and norovirus and through a new cell culture based method we are also developing an influenza vaccine in Japan.

Therapeutic Areas

  • Gastroenterology

  • Oncology

  • Central Nervous System

  • Cardiovascular & Metabolic

  • &

  • Vaccines

Medicines

  • Major Products

  • Growth Products

  • VELCADE®

  • ENTYVIO®

  • CANDESARTAN

  • AZILVA®

  • LEUPRORELIN

  • DEXILANT®

  • PANTOPRAZOLE

  • TAKECAB®

  • LANSOPRAZOLE

  • BRINTELLIX®

Near-term Growth

  • Gastroenterology

  • Oncology

  • Value Brands

    in Emerging Markets

    (Off-patent brands and over-the-counter products)

70+

Countries with market presence

30,000+

Employees worldwide

Key products and pipeline

Key products and pipeline

Recently Launched and Filed

Gastroenterology

  • ENTYVIO®
    (vedolizumab)
    Ulcerative Colitis and Crohn’s Disease

  • TAKECAB®
    (vonoprazan fumarate)
    Acid-related Diseases

Oncology

  • ADCETRIS®
    (brentuximab vedotin)
    Hodgkin Lymphoma

  • NINLARO®
    (ixazomib)
    Multiple Myeloma

Central Nervous System

  • BRINTELLIX®
    (vortioxetine)
    Major Depressive Disorder

  • Glatiramer (COPAXONE®)
    Multiple Sclerosis

Cardiovascular & Metabolic

  • NESINA®
    (alogliptin)
    Type 2 Diabetes

  • CONTRAVE®
    (naltrexone HCl and bupropion HCl)
    Obesity

  • AZILVA®
    (azilsartan)
    Hypertension

  • ZAFATEK®
    (trelagliptin succinate)
    Type 2 Diabetes

Key Late-stage Pipeline

Gastroenterology

  • TAK-114
    Ulcerative Colitis

Oncology

  • TAK-385
    Prostate Cancer

  • TAK-228/MLN0128
    Breast Cancer

  • Alisertib
    Lung Cancer

Central Nervous System

  • Rasagiline (AZILECT®)
    Parkinson’s Disease

  • AD-4833 TOMM40
    Alzheimer’s Disease

Cardiovascular & Metabolic

  • TAK-272
    Diabetic Nephropathy

Vaccines

  • TAK-850
    Influenza

  • TAK-003
    Dengue

  • TAK-214
    Norovirus

Other therapeutic areas

  • Namilumab
    Psoriasis and Rheumatoid Arthritis

December 2015

“ I joined Takeda because of its strength in fundamental research. What is most appealing to me is being able to collaborate with researchers from all over the world. ”

Dr. Hideo Fukui
Associate Research Director Takeda

Our Recent Key Products and Pipeline Milestones

ENTYVIO® launched in 19 countries worldwide; approved in Brazil and filed in Russia
TAKECAB® and ZAFATEK® launched in Japan in 2015
BRINTELLIX® and CONTRAVE® approved in the U.S. in 2013 and 2014
• Expanded reach of ADCETRIS® with approval in Brazil and filing in Russia
NINLARO® launched in the U.S. in December 2015; filed and granted accelerated assessment from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)

Innovation is our DNA

Bringing science from the lab to patients worldwide

Innovative research and development is at the heart of Takeda’s strategic roadmap. We aim to make an impact on patients’ lives by translating science into life-changing medicines.

Our portfolio includes: ENTYVIO®, a humanized monoclonal antibody for ulcerative colitis and Crohn’s disease; NINLARO®, potentially the first oral proteasome inhibitor for relapsed and/or refractory multiple myeloma; and vaccine candidates against dengue virus and norovirus.

We are also expanding our research efforts in the development of biologics – products that represent cutting-edge biomedical research and offer the opportunity to target identified pathways and steps within the disease mechanism.

Fundamental to our future is innovation – we foster a culture where ideas thrive to solve problems and help patients worldwide.

Exemplary collaborations

Center for iPS Cell Research Application
– Kyoto University

Takeda and the Center for iPS Cell Research and Application of Kyoto University have partnered to develop clinical applications of induced pluripotent stem cells (iPS). Applications are focused on areas that include heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy. Based at Takeda’s Shonan Research Center in Fujisawa, Japan, this 10-year collaboration will be directed by Professor Shinya Yamanaka, a Nobel laureate in this field.

Tri-Institutional Therapeutics Discovery Institute

Takeda is the industry partner in an unprecedented
collaboration with three academic institutions.
This unique partnership is an independent, nonprofit
institute with its own scientific advisory board
and board of directors and builds a strong bridge
to expedite early-stage drug discovery into
innovative treatments and therapies for patients.

Advancing Oncology

Since 2009, Seattle Genetics, Inc., and Takeda
have partnered to develop and commercialize
ADCETRIS® outside the U.S. and Canada for the
treatment of relapsed and refractory Hodgkin
lymphoma and systemic anaplastic large cell
lymphoma. This collaboration has enabled access
to ADCETRIS® for more than 20,000 patients
in more than 55 countries since 2012.

Accelerating innovations through partnerships

Together we achieve more

Scientific progress is based on the exchange of ideas. We partner with academia and other pharmaceutical/biotech companies to accelerate innovation and bring together the best and the brightest within our industry.

Our collaborations are open and offer a network to exchange knowledge and build on each of our areas of expertise. Together we have the potential to impact even more patients and society as a whole.

The partnerships we build are not limited to research alone. We also enter into co-marketing and co-promotional agreements with other companies. We share our commercial capabilities and as a result broaden access to our medicines in markets around the world.

“I love that my colleagues at Takeda are driven and passionate about the work we all do. It’s inspiring to come to work every day knowing that I’m surrounded by people determined to improve the health and quality of life for both patients and their families.”

Dr. Nitya Durvasula
Senior Research Scientist
Takeda

“I may be on the road most days, but I am part of a team. I have the greatest support system of managers and colleagues. They are my family.”

Brooke Whitman
Specialty Sales Representative
Takeda

 

Our corporate philosophy

Takeda-ism – our commitment to acting with integrity – is at the forefront of our business. We work to the highest ethical standards, operate with fairness and honesty and persevere to achieve our ideals.

“ Every employee contributes to our vision for a global patient- and customer-centric pharmaceutical company – a place where a meritocratic culture and the shared ethics and values of Takeda-ism enable a diverse team of employees to thrive.

We at Takeda can change the lives of patients around the world.”

Christophe Weber
President & CEO
Takeda

A stimulating work environment

Global teams with a common goal

Across our company, Takeda employees offer different elements that together create a stronger whole. Through our global footprint we attract dedicated people from a variety of cultures, countries and areas of expertise. This diversity allows us to approach our work with a unique perspective providing opportunities for growth at every turn.

We have a collaborative and stimulating environment where we:

• Support and foster talent
• Are passionate about making a difference
• Work towards a common goal to discover, develop, produce and market medicines and vaccines

And where every employee contributes to making a difference to the lives of patients worldwide.

10 years
Length of the Takeda Initiative program supporting the Global Fund to Fight AIDS, Tuberculosis & Malaria in Africa
(2010–2019)
1/45
Member of 45 UN Global Compact LEAD companies promoting the implementation and widespread adoption of the UN Global Compact principles
¥3.9bn
Donated for Great East Japan Earthquake Assistance
(2011–2020)
25%
Fiscal 2020 CO2 emissions reduction target
(from fiscal 2005 levels)
122
Number of endangered plant species preserved in the Takeda Garden for Medicinal Plant Conservation, Kyoto
(as of March 31, 2015)
1,454
Accumulated number of scientific researchers worldwide awarded scholarships from the Takeda Science Foundation
(as of March 31, 2015)

A Thousand Origami Cranes

The crane, known in Japan as the “tsuru” – said to live for a thousand years – has for generations embodied hope and good fortune.

An ancient Japanese legend, or “senbazuru,” promises that anyone who folds one thousand origami cranes will be granted a wish. Some wish for good luck, longevity or recovery from illness.

This sculpture of colorful origami cranes was created by Katsuhiko Hibino and hangs in Takeda’s Shonan Research Center entrance, with our collective hope and wish for better health for everyone.

We’re proud of our 230-year heritage, as this defines who we are and where we are going. We are inspired and motivated by our patients… their stories, their lives, their hopes for better health, their dreams for a brighter future

Our mission extends beyond our core business

We do more than develop medicines

We connect people to resources, services and knowledge that improve their health and enrich their lives.

Takeda’s operations have become global in scale, demands concerning corporate social responsibility have increased. As a corporate citizen, we aim to take the initiative to address social issues in areas where we can leverage our strengths. In this way, Takeda’s relationships with society are an integral part of its business development.

We are committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.

Better Health, Brighter Future

For a full understanding of Takeda, please download our Corporate Brochure

Select Color: